Daniel Wilson to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Daniel Wilson has written about Diabetes Mellitus, Type 2.
Connection Strength
0.603
-
Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Expert Rev Clin Pharmacol. 2022 May; 15(5):501-513.
Score: 0.452
-
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022 01; 33(1):225-237.
Score: 0.108
-
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008 Aug; 83(8):870-9.
Score: 0.043